[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350487-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-350487-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","comparative-overall-survival-in-t4n0-and-t2-3n1-non-metastatic-colon-cancer-a-retrospective-cohort-study","Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer - a retrospective cohort study","","This retrospective single-center study compared long-term oncologic outcomes between non-metastatic T4N0 colon cancer and T2–3N1 disease. Histologically confirmed, non-metastatic colon adenocarcinoma patients undergoing curative-intent surgery from 1999–2020 were grouped as T4N0 (n=78) or T2–3N1 (n=195). Overall survival and disease-free survival were estimated by Kaplan–Meier and tested with log-rank methods. After 72 months median follow-up, T4N0 showed significantly worse OS and higher recurrence, with T4N0, older age, vascular invasion, and omission of oxaliplatin-based adjuvant chemotherapy independently predicting poorer OS.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comparative-overall-survival-in-t4n0-and-t2-3n1-non-metastatic-colon-cancer-a-retrospective-cohort-study/350487/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comparative-overall-survival-in-t4n0-and-t2-3n1-non-metastatic-colon-cancer-a-retrospective-cohort-study/350487.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What question did the study address about T4N0 vs T2–3N1 colon cancer?","Question",{"text":63,"@type":64},"The study compared long-term oncologic outcomes between patients with non-metastatic T4N0 colon cancer and those with T2–3N1 disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were overall survival and disease-free survival evaluated?",{"text":68,"@type":64},"Overall survival and disease-free survival were estimated using the Kaplan–Meier method and compared with log-rank tests. Prognostic factors were assessed with univariate and multivariate Cox proportional hazards models.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main survival findings after follow-up?",{"text":72,"@type":64},"After a median follow-up of 72 months, T4N0 patients had significantly worse overall survival than T2–3N1 patients, with lower five-year overall survival rates (66.6% vs 79.8%).",{"name":74,"@type":61,"acceptedAnswer":75},"Which factors were independently associated with poorer overall survival?",{"text":76,"@type":64},"Multivariate analysis identified pathological T4N0 stage, age ≥65 years, vascular invasion, and omission of oxaliplatin-based adjuvant chemotherapy as independent predictors of poorer overall survival.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},350487,1790173916,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","original article  \nComparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer:  \na retrospective cohort study  \nFırat Akagunduz, Ali Kaan Güren, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Ahmet Demirel, Yesim Ağyol, Pınar Erel, Abdussamet Çelebi, Selver Işik, Ezgi Coban, Murat Sarı, Ibrahim Vedat Bayoğlu, Osman Köstek, Nazım Can Demircan  \nFrom the Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Türkiye  \nCorrespondence: Dr. Fırat Akagunduz · Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Türkiye · [fratakagunduz0@gmail.com](fratakagunduz0@gmail.com) · ORCID: [https://orcid.org/0000-](https://orcid.org/0000-)[ ](https://orcid.org/0000-)[0001-7969-9464](0001-7969-9464)  \nCitation: Akagunduz F, Güren AK, Kocaaslan E, Paçaci B, Tunç MA, Demirel A, et al. omparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study. Ann Saudi Med 2026; 46(3): 169-177. DOI:  \n10.5144/0256-4947.2026.169 Received: February 8, 2026  \nAccepted: April 8, 2026  \nPublished: June 5, 2026  \nCopyright: Copyright © 2026, Annals of Saudi Medicine, Saudi Arabia. This is an open access article under the Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License (CC BY-NC-ND) . The details of which can be accessed at [http://](http://)[ ](http://)[creativecommons. org/licenses/by](creativecommons. org/licenses/by)nc-nd/4.0/  \nFunding: None.  \nBACKGROUND: The prognostic significance of pathological T stage relative to nodal involvement in colon cancer remains controversial. Emerging evidence suggests that patients with T4N0 disease may experience outcomes comparable to or worse than those with nodepositive disease.  \nOBJECTIVES: This study aimed to compare long-term oncologic outcomes between patients with non-metastatic T4N0 colon cancer and those with T2–3N1 disease.  \nDESIGN: Retrospective  \nSETTINGS: Single-center  \nPATIENTS AND METHODS: Retrospective analysis of patients with histologically confirmed, non-metastatic colon adenocarcinoma who underwent curative-intent surgery between 1999 and 2020. Patients were categorized into T4N0 and T2–3N1 groups.  \nMAIN OUTCOME MEASURES: Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method and compared with log-rank tests. Prognostic factors were assessed using univariate and multivariate Cox proportional hazards models.  \nSAMPLE SIZE: A total of 273 patients were included, of whom 78 (28.6%) were staged as T4N0 and 195 (71.4%) as T2–3N1 .  \nRESULTS: After a median follow-up of 72 months, patients with T4N0 disease showed significantly worse OS than those with T2–3N1 disease (HR=1.72, 95% CI 1.06–2.75; P= .02) . Five-year OS rates were 66.6% and 79.8% in the T4N0 and T2–3N1 groups, respectively. On multivariate analysis, pathological T4N0 stage (HR=1.74, 95% CI 1.03–2.93; P= .03), age ≥65 years, vascular invasion, and omission of oxaliplatinbased adjuvant chemotherapy independently predicted poorer OS. Stage T4N0 was also associated with higher locoregional and distant recurrence rates, with increased peritoneal involvement. CONCLUSIONS: Non-metastatic T4N0 colon cancer is associated with less favorable long-term survival and higher recurrence rates compared with T2–3N1 disease, supporting its classification as a biologically aggressive subgroup that may benefit from treatment strategies similar to selected stage III colon cancers.  \nLIMITATIONS: The retrospective, single-center design may introduce selection bias, and limited molecular data precluded detailed subgroup analyses.  \nCONFLICT OF INTEREST: None.  \nKEYWORDS: Colon cancer, T4N0, adjuvant chemotherapy  \nANN SAUDI MED 2026 MAY-JUNE WWW.ANNSAUDIMED.NET 169  \noriginal article  \nOVERALL SURVIVAL INT4N0 VST2–3N1 COLON CANCER  \nColorectal cancer continues to be a leading  \ncause of cancer-related morbidi","cbCaisQ8XSTzK5co","https://ap.wps.com/l/cbCaisQ8XSTzK5co","pdf",1031332,"English","# Background\n## Objectives\n## Design\n## Patients and Methods\n## Main Outcome Measures\n## Results\n## Conclusions\n## Limitations\n## Conflict of Interest","[{\"question\":\"What question did the study address about T4N0 vs T2–3N1 colon cancer?\",\"answer\":\"The study compared long-term oncologic outcomes between patients with non-metastatic T4N0 colon cancer and those with T2–3N1 disease.\"},{\"question\":\"How were overall survival and disease-free survival evaluated?\",\"answer\":\"Overall survival and disease-free survival were estimated using the Kaplan–Meier method and compared with log-rank tests. Prognostic factors were assessed with univariate and multivariate Cox proportional hazards models.\"},{\"question\":\"What were the main survival findings after follow-up?\",\"answer\":\"After a median follow-up of 72 months, T4N0 patients had significantly worse overall survival than T2–3N1 patients, with lower five-year overall survival rates (66.6% vs 79.8%).\"},{\"question\":\"Which factors were independently associated with poorer overall survival?\",\"answer\":\"Multivariate analysis identified pathological T4N0 stage, age ≥65 years, vascular invasion, and omission of oxaliplatin-based adjuvant chemotherapy as independent predictors of poorer overall survival.\"}]","Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer - a retrospective cohort study | PDF",1790089279,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8797b82d9dbeae393b909477eefbc46b.webp",983,1310,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bfa467806bd84ce8cc3341b1718fde4.webp",982,1309,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22363209f49bfd19c11d177e37a8569e.webp",981,1308,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9d0293edc4d670faf782d28d533b7d3.webp",980,1306]